Arix Bioscience Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	1.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Arix Bioscience non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Tom Davidson	COO & CFO	less than a year	Nessun dato	Nessun dato
Laura Craig	Investor Relations Officer	less than a year	Nessun dato	Nessun dato
Tassos Konstantinou	Managing Director	less than a year	Nessun dato	Nessun dato
Jade Fletcher	Financial Controller	1.1yrs	Nessun dato	Nessun dato
Felix Breyer	Associate	no data	Nessun dato	Nessun dato
Roy Bartel-Taverner	Analyst	no data	Nessun dato	Nessun dato

0.9yrs

Durata media

Gestione esperta: Il team dirigenziale di 3HY non è considerato esperto (durata media 0.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Peregrine David Euan Moncreiffe	Independent Non-Executive Chairman	2.8yrs	UK£150.00k	0.58% € 1.2m
Andrew Smith	Independent Non-Executive Director	1.5yrs	UK£33.00k	Nessun dato
Debra Barker	Senior Independent Director	1.5yrs	UK£38.00k	0.040% € 83.2k

1.5yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 3HY non è considerato esperto (durata media del mandato 1.5 anni), il che suggerisce un nuovo consiglio.

Arix Bioscience Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Arix Bioscience plc Announces Resignation of Directors

Independent Non-Executive Chairman recently bought €79k worth of stock

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Independent Non-Executive Chairman recently bought €87k worth of stock

Independent Non-Executive Chairman recently bought €243k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Recent updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Investor sentiment improves as stock rises 16%

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought €79k worth of stock

New minor risk - Share price stability

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023

New minor risk - Insider selling

Independent Non-Executive Chairman recently bought €87k worth of stock

Full year 2022 earnings released

Independent Non-Executive Chairman recently bought €243k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders.

Less than half of directors are independent

Independent Non-Executive Chairman recently bought €90k worth of stock

Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders for $68.2 million.

First half 2022 earnings released

Arix Bioscience plc Announces Board and Committee Changes

Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022

Arix Bioscience plc, Annual General Meeting, Jun 07, 2022

Full year 2021 earnings released: UK£0.48 loss per share (vs UK£0.97 profit in FY 2020)

Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022

Less than half of directors are independent

Investor sentiment improved over the past week

Managing Director Christian Schetter has left the company

First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)

Executive Chairman Naseem Amin has left the company

Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.

Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)

Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day high: €2.36

Executive Chairman recently bought €416k worth of stock

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: €1.82

Market bids up stock over the past week

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.

Market bids up stock over the past week

New 90-day high: €1.70

New 90-day high: €1.16

New 90-day high - €1.08

Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media